Business
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" VICTORIA, British Columbia--(BUSINESS WIRE)--\n\nAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 59th European Renal Association (ERA) Congress and at the European Congress of Rheumatology, European Alliance of Associations for Rheumatology (EULAR) 2022. The 2022 ERA Congress will take place virtually and in Paris on May 19-22 and the EULAR 2022 Congress will take place virtually and in Denmark on June 1-4.\n\n“Aurinia continues to expand its clinical evidence supporting LUPKYNIS as a reliable treatment option for people and HCPs working to protect their patients’ kidneys from the devastating impact of lupus nephritis,” said Neil Solomons, M.D., Chief Medical Officer at Aurinia. “We look forward to presenting new data for LUPKYNIS at the ERA and EULAR Congresses, including our results from the two-year AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS for the treatment of lupus nephritis.”\n\nScientific programs and information for the ERA Congress and EULAR Congress are available online at https://www.era-online.org/en/paris2022/ and https://congress.eular.org/index.cfm respectively. The presentation details are as follows.\n\nERA Congress 2022 Presentations:\n\nTitle: “Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study”\nPresenting author: Y.K. Onno Teng, M.D., Ph.D., President of the National Foundation of the Autoimmune Research & Collaboration Hubs (ARCH)\nDate: Friday, May 20, 2022\nTime: 17:00-18:30 CEST\n\nTitle: “Early Reductions in Proteinuria with Voclosporin Treatment across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials”\nPresenting author: Anca Askanase, M.D., M.P.H., Columbia University Medical Center\nDate: Friday, May 20, 2022\nTime: 17:43-17:58 CEST\n\nEULAR Congress 2022 Presentations and Posters:\n\nTitle: “Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study”\nPresenting author: Amit Saxena, M.D., NYU School of Medicine\nDate: Friday, June 3, 2022\nTime: 12:26-12:34 CEST\n\nTitle: “Voclosporin is Effective in Achieving Proteinuria Treatment Ta...